The BioMedWire Podcast

By [email protected]News Business News

The BioMedWire Podcast episodes

June 26Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion by 2030. New inhibitor classes are emerging as the next major wave. Sitting at the forefront of this shift is Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF), (Profile) a Canadian clinical-stage oncology company developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor that targets a DNA repair enzyme involved in multiple DNA repair pathways. As the field races to find the next generation of synthetic lethality assets, Onco-Innovations occupies a unique space as it strengthens its position in the biopharmaceutical and biotechnology sector, along with other leading companies, such as AstraZeneca plc (NYSE: AZN), Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD) and Foghorn Therapeutics Inc. (NASDAQ: FHTX), that are focused on developing therapies for serious diseases, particularly cancer.
PARP inhibitors transformed oncology when they arrived in the clinic more than a decade ago, but they are only one entry point into a complex biological system.
Onco-Innovations holds exclusive global rights to a foundational portfolio of PNKP inhibitor technology.
The company’s preclinical program has produced specific, measurable results that support the biological rationale for PNKP inhibition in solid tumors.
ONCO holds exclusive global rights across three distinct layers of protection, each reinforcing the others.
To read the Full Publication, visit https://ibn.fm/Lhc3W
For further information about Onco-Innovations, visit the Onco-Innovations profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
22 min
June 26Next-Generation DNA Repair Therapies Open New Frontiers in Oncology [Video Edition]
BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion by 2030. New inhibitor classes are emerging as the next major wave. Sitting at the forefront of this shift is Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF), (Profile) a Canadian clinical-stage oncology company developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor that targets a DNA repair enzyme involved in multiple DNA repair pathways. As the field races to find the next generation of synthetic lethality assets, Onco-Innovations occupies a unique space as it strengthens its position in the biopharmaceutical and biotechnology sector, along with other leading companies, such as AstraZeneca plc (NYSE: AZN), Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD) and Foghorn Therapeutics Inc. (NASDAQ: FHTX), that are focused on developing therapies for serious diseases, particularly cancer.
PARP inhibitors transformed oncology when they arrived in the clinic more than a decade ago, but they are only one entry point into a complex biological system.
Onco-Innovations holds exclusive global rights to a foundational portfolio of PNKP inhibitor technology.
The company’s preclinical program has produced specific, measurable results that support the biological rationale for PNKP inhibition in solid tumors.
ONCO holds exclusive global rights across three distinct layers of protection, each reinforcing the others.
To read the Full Publication, visit https://ibn.fm/Lhc3W
For further information about Onco-Innovations, visit the Onco-Innovations profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
22 min
June 05How Advanced Drug Delivery Could Improve Existing Cancer Treatments
BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy centers on leveraging platform technologies that may support multiple therapeutic applications across oncology and rare disease markets rather than relying solely on a single drug candidate. Oncotelic is one of several companies, including Northwest Biotherapeutics Inc. (OTCQB: NWBO), Sangamo Therapeutics Inc. (OTCQB: SGMO), HIVE Digital Technologies Ltd. (NASDAQ: HIVE) and Iovance Biotherapeutics Inc. (NASDAQ: IOVA), that are building scalable platforms — whether cancer immunotherapy, genomic medicine, AI/data infrastructure or cell therapy — rather than single-product biotechnology stories alone.
Biotechnology companies are increasingly exploring alternative strategies focused on improving the performance of already-approved therapeutics.
Oncotelic Therapeutics is advancing delivery-focused technologies intended to potentially improve exposure consistency and therapeutic performance.
Nanotechnology-enabled drug delivery has emerged as one of the fastest-growing segments within oncology therapeutics.
Oncotelic Therapeutics is pursuing an integrated platform strategy through both Deciparticle and PDAOAI, the company’s AI-enhanced biomedical infrastructure initiative.
Investor attention across biotechnology is increasingly shifting toward companies developing differentiated platform technologies capable of supporting multiple drugs and therapeutic indications.
To read the full publication, visit: https://ibn.fm/KV2Tw
For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
22 min
June 05How Advanced Drug Delivery Could Improve Existing Cancer Treatments [Video Edition]
BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy centers on leveraging platform technologies that may support multiple therapeutic applications across oncology and rare disease markets rather than relying solely on a single drug candidate. Oncotelic is one of several companies, including Northwest Biotherapeutics Inc. (OTCQB: NWBO), Sangamo Therapeutics Inc. (OTCQB: SGMO), HIVE Digital Technologies Ltd. (NASDAQ: HIVE) and Iovance Biotherapeutics Inc. (NASDAQ: IOVA), that are building scalable platforms — whether cancer immunotherapy, genomic medicine, AI/data infrastructure or cell therapy — rather than single-product biotechnology stories alone.
Biotechnology companies are increasingly exploring alternative strategies focused on improving the performance of already-approved therapeutics.
Oncotelic Therapeutics is advancing delivery-focused technologies intended to potentially improve exposure consistency and therapeutic performance.
Nanotechnology-enabled drug delivery has emerged as one of the fastest-growing segments within oncology therapeutics.
Oncotelic Therapeutics is pursuing an integrated platform strategy through both Deciparticle and PDAOAI, the company’s AI-enhanced biomedical infrastructure initiative.
Investor attention across biotechnology is increasingly shifting toward companies developing differentiated platform technologies capable of supporting multiple drugs and therapeutic indications.
To read the full publication, visit: https://ibn.fm/KV2Tw
For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
22 min
June 02 BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)
Disseminated on behalf of Quantum BioPharma, may include paid advertisements.
AUSTIN, Texas, June 2, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies.
To begin the interview, Durkacz outlined Quantum BioPharma’s primary focus on advancing its lead multiple sclerosis drug candidate, Lucid-MS.
“Quantum BioPharma is focused on a drug candidate that is trying to address an issue that exists today for people that suffer from multiple sclerosis,” he said. “If you know anybody that has the disease, you will see that over time there is a progression where they begin to lose control of parts of their body or sometimes their entire body. What our main drug candidate focus, Lucid-MS, is trying to do is reverse that damage that’s been done to people’s mobility. We believe that is something that is not addressed in any drug or therapy today in the world. There are almost three million people that suffer from this debilitating disease.”
Join IBN’s Stuart Smith for a conversation with Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma, as he discusses the company’s Lucid-MS development program, its unbuzzd™ commercial strategy and the milestones ahead for 2026.
To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com
The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
18 min
June 02 BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) [Video Edition]
Disseminated on behalf of Quantum BioPharma, may include paid advertisements.
AUSTIN, Texas, June 2, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies.
To begin the interview, Durkacz outlined Quantum BioPharma’s primary focus on advancing its lead multiple sclerosis drug candidate, Lucid-MS.
“Quantum BioPharma is focused on a drug candidate that is trying to address an issue that exists today for people that suffer from multiple sclerosis,” he said. “If you know anybody that has the disease, you will see that over time there is a progression where they begin to lose control of parts of their body or sometimes their entire body. What our main drug candidate focus, Lucid-MS, is trying to do is reverse that damage that’s been done to people’s mobility. We believe that is something that is not addressed in any drug or therapy today in the world. There are almost three million people that suffer from this debilitating disease.”
Join IBN’s Stuart Smith for a conversation with Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma, as he discusses the company’s Lucid-MS development program, its unbuzzd™ commercial strategy and the milestones ahead for 2026.
To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com
The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
18 min
May 15CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (“CNS”). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), are working within a broader industry shift toward advanced delivery platforms designed to bypass traditional barriers and facilitate rapid, targeted access to the brain. Oncotelic’s approach, which includes a proprietary intranasal nose-to-brain (“N2B”) system that enables rapid therapeutic delivery, reflects a growing recognition that solving CNS delivery, not just drug discovery, may be key to unlocking the next generation of therapies. Oncotelic joins a group of leading biopharma companies focused on cutting-edge therapeutic platforms and large-scale drug development in a range of treatment areas, including Biogen Inc. (NASDAQ: BIIB), Moderna Inc. (NASDAQ: MRNA), CytoDyn Inc. (OTCQB: CYDY) and Northwest Biotherapeutics Inc. (OTCQB: NWBO).
Oncotelic Therapeutics is focused on advancing technologies designed to bypass or overcome BBB limitations.
The global burden of Alzheimer’s disease and related dementias is increasing at an unprecedented rate.
Beyond chronic diseases, CNS drug delivery is also a critical factor in biodefense and national security.
As traditional drug-delivery approaches continue to face limitations, alternative methods designed to bypass the BBB, such as those being developed by Oncotelic, are gaining increasing attention.
The future of CNS therapeutics is increasingly centered on platform-based solutions rather than single-drug strategies.
For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
20 min
May 15CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities [Video Edition]
BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (“CNS”). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), are working within a broader industry shift toward advanced delivery platforms designed to bypass traditional barriers and facilitate rapid, targeted access to the brain. Oncotelic’s approach, which includes a proprietary intranasal nose-to-brain (“N2B”) system that enables rapid therapeutic delivery, reflects a growing recognition that solving CNS delivery, not just drug discovery, may be key to unlocking the next generation of therapies. Oncotelic joins a group of leading biopharma companies focused on cutting-edge therapeutic platforms and large-scale drug development in a range of treatment areas, including Biogen Inc. (NASDAQ: BIIB), Moderna Inc. (NASDAQ: MRNA), CytoDyn Inc. (OTCQB: CYDY) and Northwest Biotherapeutics Inc. (OTCQB: NWBO).
Oncotelic Therapeutics is focused on advancing technologies designed to bypass or overcome BBB limitations.
The global burden of Alzheimer’s disease and related dementias is increasing at an unprecedented rate.
Beyond chronic diseases, CNS drug delivery is also a critical factor in biodefense and national security.
As traditional drug-delivery approaches continue to face limitations, alternative methods designed to bypass the BBB, such as those being developed by Oncotelic, are gaining increasing attention.
The future of CNS therapeutics is increasingly centered on platform-based solutions rather than single-drug strategies.
For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
20 min
May 15The Next Generation of the GLP-1 Revolution Is Already Underway
BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), (Profile) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in one of the fastest-growing pharmaceutical markets in history. SureNano is one of the emerging microcap companies operating in the GLP space, forming part of a group of companies leading the way in the GLP-1 space, including Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE).
As the global obesity crisis continues, GLP-1 receptor agonists have rapidly emerged as one of the most important therapeutic breakthroughs in metabolic medicine.
SureNano Science is advancing GEP-44 as a next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs.
The global GLP-1 market could total more than $200 billion by 2035 as patient adoption expands and broader therapeutic applications emerge.
Beyond therapeutic innovation itself, SureNano Science is also pursuing differentiated drug-delivery technologies designed to improve patient accessibility and adherence.
SureNano Science is also evaluating early-stage opportunities that could broaden the long-term scope of its therapeutic and delivery technology portfolio, including exposure to Ibogaine.
For further information about SureNano Science Ltd., visit the SureNano Science profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
23 min
May 15The Next Generation of the GLP-1 Revolution Is Already Underway [Video Edition]
BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), (Profile) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in one of the fastest-growing pharmaceutical markets in history. SureNano is one of the emerging microcap companies operating in the GLP space, forming part of a group of companies leading the way in the GLP-1 space, including Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE).
As the global obesity crisis continues, GLP-1 receptor agonists have rapidly emerged as one of the most important therapeutic breakthroughs in metabolic medicine.
SureNano Science is advancing GEP-44 as a next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs.
The global GLP-1 market could total more than $200 billion by 2035 as patient adoption expands and broader therapeutic applications emerge.
Beyond therapeutic innovation itself, SureNano Science is also pursuing differentiated drug-delivery technologies designed to improve patient accessibility and adherence.
SureNano Science is also evaluating early-stage opportunities that could broaden the long-term scope of its therapeutic and delivery technology portfolio, including exposure to Ibogaine.
For further information about SureNano Science Ltd., visit the SureNano Science profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
23 min